Research interests
Angiogenic proteins as biomarkers in peripheral artery disease[8]
As of 2023 · Last known relationship
Christopher Dale Kontos is a Duke cardiologist and physician-scientist whose leadership in physician-scientist training complements research on angiogenesis and vascular remodeling. He earned his M.D. from Virginia Commonwealth University in 1989, completed medicine residency at the Medical College of Virginia from 1989 to 1993, and trained in cardiology at Duke University Medical Center from 1993 to 1997. Duke lists him as Professor of Medicine, Professor of Pharmacology and Cancer Biology, Professor of Cell Biology, and Director of the Medical Scientist Training Program. He has been a member of the Duke Cancer Institute since 1993. His clinical interests include cardiology and cardiac evaluation of athletes, while his laboratory studies endothelial receptor tyrosine kinase signaling, vascular growth, and remodeling in conditions including peripheral artery disease, atherosclerosis, and cancer.
Each topic is linked to its supporting source in Sources.
Training includes Talk sharing insights from Duke and Vanderbilt's accomplishment of a seven-year Time to Degree (TTD) for physician-scientist trainees, Cardiology at Duke University Medical Center, Medicine at Medical College of Virginia, and Professor of Cell Biology, plus 6 more records.
Explore education and trainingAs of 2023
As of 1997
As of 1993
As of 2022
As of 2017
As of 2017
As of 2009
As of 1993
Completed 1989
Angiogenic proteins as biomarkers in peripheral artery disease[8]
Angiogenic signaling in skeletal muscle, including exercise-induced angiogenesis[8]
Molecular mechanisms of angiogenesis and vascular remodeling[6]
PTEN regulation of vascular cell growth and remodeling, including gene therapy for prevention of vein graft disease[8]
Regulation of endothelial metabolism by the Tie1 receptor tyrosine kinase[10]
Signal transduction, activation, and downregulation of endothelial receptor tyrosine kinases, including Tie1, Tie2, VEGFR-1, and VEGFR-2[8]